Role of inflammation following an acute myocardial infarction : design of INFINITY
After a myocardial infarction, the inflammatory response is connected to major adverse outcomes such as ischemia-reperfusion injury, adverse cardiac remodeling, infarct size and poor prognosis. INFlammatIoN amI sTudY (INFINITY) is a multicenter, prospective, observational, cohort study designed to investigate the prognostic role of the cytokines IL-6, IL-10, IL-18 and IL-17 and the adipokines leptin, apelin and chemerin in patients with acute coronary syndrome. The study will test if these inflammatory biomarkers reflect different clinical manifestations of coronary artery disease and have a prognostic role in a 6-month follow-up period. This study represents an opportunity to investigate further the prognostic role of a selected combination of proinflammatory and anti-inflammatory biomarkers in the prognosis and risk stratification of acute coronary syndrome patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Biomarkers in medicine - 17(2023), 23 vom: 01. Dez., Seite 971-981 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mitsis, Andreas [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute coronary syndrome |
|---|
| Anmerkungen: |
Date Completed 23.01.2024 Date Revised 28.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/bmm-2023-0491 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367260727 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367260727 | ||
| 003 | DE-627 | ||
| 005 | 20240229234757.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240118s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/bmm-2023-0491 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1311.xml |
| 035 | |a (DE-627)NLM367260727 | ||
| 035 | |a (NLM)38235565 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mitsis, Andreas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Role of inflammation following an acute myocardial infarction |b design of INFINITY |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.01.2024 | ||
| 500 | |a Date Revised 28.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a After a myocardial infarction, the inflammatory response is connected to major adverse outcomes such as ischemia-reperfusion injury, adverse cardiac remodeling, infarct size and poor prognosis. INFlammatIoN amI sTudY (INFINITY) is a multicenter, prospective, observational, cohort study designed to investigate the prognostic role of the cytokines IL-6, IL-10, IL-18 and IL-17 and the adipokines leptin, apelin and chemerin in patients with acute coronary syndrome. The study will test if these inflammatory biomarkers reflect different clinical manifestations of coronary artery disease and have a prognostic role in a 6-month follow-up period. This study represents an opportunity to investigate further the prognostic role of a selected combination of proinflammatory and anti-inflammatory biomarkers in the prognosis and risk stratification of acute coronary syndrome patients | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a acute coronary syndrome | |
| 650 | 4 | |a adipokines | |
| 650 | 4 | |a apelin | |
| 650 | 4 | |a chemerin | |
| 650 | 4 | |a cytokines | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a interleukin-6 | |
| 650 | 4 | |a leptin | |
| 650 | 4 | |a myocardial infarction | |
| 650 | 4 | |a prognosis | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Avraamides, Panayiotis |e verfasserin |4 aut | |
| 700 | 1 | |a Lakoumentas, John |e verfasserin |4 aut | |
| 700 | 1 | |a Kyriakou, Michaela |e verfasserin |4 aut | |
| 700 | 1 | |a Sokratous, Stefanos |e verfasserin |4 aut | |
| 700 | 1 | |a Karmioti, Georgia |e verfasserin |4 aut | |
| 700 | 1 | |a Drakomathioulakis, Michail |e verfasserin |4 aut | |
| 700 | 1 | |a Theodoropoulos, Konstantinos C |e verfasserin |4 aut | |
| 700 | 1 | |a Nasoufidou, Athina |e verfasserin |4 aut | |
| 700 | 1 | |a Evangeliou, Alexandros |e verfasserin |4 aut | |
| 700 | 1 | |a Vassilikos, Vassilios |e verfasserin |4 aut | |
| 700 | 1 | |a Fragakis, Nikolaos |e verfasserin |4 aut | |
| 700 | 1 | |a Ziakas, Antonios |e verfasserin |4 aut | |
| 700 | 1 | |a Tzikas, Stergios |e verfasserin |4 aut | |
| 700 | 1 | |a Kassimis, George |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomarkers in medicine |d 2007 |g 17(2023), 23 vom: 01. Dez., Seite 971-981 |w (DE-627)NLM184946271 |x 1752-0371 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2023 |g number:23 |g day:01 |g month:12 |g pages:971-981 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/bmm-2023-0491 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2023 |e 23 |b 01 |c 12 |h 971-981 | ||